Gsk (GSK) Operating Income (2009 - 2026)
Gsk (GSK) posted quarterly Operating Income of $645.3 million for Q2 2026, down 76.09% year-over-year from $2.7 billion in Q2 2025, and down 79.12% quarter-over-quarter from $3.1 billion in Q1 2026.
Gsk (GSK) Operating Income (2009 - 2026) Analysis & Trends
Gsk's Operating Income history runs 18 years deep, the most recent figure standing at $645.3 million for Q2 2026.
- In Q2 2026, Operating Income fell 76.09% year-over-year to $645.3 million; the TTM figure through Jun 2026 stood at $12.9 billion (up 31.9% YoY), while the FY2025 annual figure was $10.5 billion, up 103.47% from the prior year.
- Operating Income for Q2 2026 stood at $645.3 million, down from $3.1 billion in the prior quarter.
- The five-year high for Operating Income was $5.6 billion in Q4 2025, with the low at $245.6 million in Q3 2024.
- The 5-year median for Operating Income is $2.7 billion (2023), against an average of $2.7 billion.
- The sharpest annual moves came in 2024 and 2025: Operating Income plunged 90.05% in 2024, then jumped 1324.82% in 2025.
- Gsk's Operating Income stood at $4.0 billion in 2022, then jumped by 32.44% to $5.2 billion in 2023, then decreased by 23.21% to $4.0 billion in 2024, then surged by 40.09% to $5.6 billion in 2025, then plunged by 88.55% to $645.3 million in 2026.
- Business Quant data shows GSK's Operating Income at $645.3 million in Q2 2026, $3.1 billion in Q1 2026, and $5.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 645.35 Mn |
| Mar 31, 2026 | 3.09 Bn |
| Dec 31, 2025 | 5.64 Bn |
| Sep 30, 2025 | 3.50 Bn |
| Jun 30, 2025 | 2.70 Bn |
| Mar 31, 2025 | 2.79 Bn |
| Dec 31, 2024 | 4.03 Bn |
| Sep 30, 2024 | 245.57 Mn |
| Jun 30, 2024 | 2.08 Bn |
| Mar 31, 2024 | 1.89 Bn |
| Dec 31, 2023 | 5.24 Bn |
| Sep 30, 2023 | 2.47 Bn |
| Jun 30, 2023 | 2.68 Bn |
| Mar 31, 2023 | 2.53 Bn |
| Dec 31, 2022 | 3.96 Bn |
| Sep 30, 2022 | 1.40 Bn |
| Jun 30, 2022 | 1.36 Bn |
| Mar 31, 2022 | 3.08 Bn |
| Dec 31, 2021 | 3.35 Bn |
| Sep 30, 2021 | 1.90 Bn |